Sharemaestro Newsreel

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 44.3% year on year to $335 million. The company's full-year revenue guidance of $1.35 billion at …

Is OPKO Health (OPK) A Bargain After Its Q2 Earnings And 52 Week High?

Thermo Fisher Scientific (TMO) Could Be 2% Undervalued After Q2 Earnings Beat

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Thermo Fisher Scientific (TMO) is back in focus after reporting second quarter results that exceeded market expectations, supported by broad-based demand and fresh regulatory clearances …

Revvity Inc (RVTY) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Revvity Inc (RVTY), noting its current risk score of 7.44 and its ranking within the Healthcare Equipment & Supplies industry. It details the company's beta value of 1.12, indicating higher volatility compared to the S&P 500. The …

Biotech Stocks Surge with Advanced Biomed Leading Gains

Advanced Biomed (ADVB) experienced a significant stock price surge of over 211% this week, driven by strong investor interest in its microfluidic technology despite not yet having commercial sales. Other biotech companies like Novocure (NVCR), Medpace (MEDP), and SciSparc (SPRC) also showed substantial gains …

ALEC|Alector Inc|Price:1.640|Chg%:+0.120

Alector Inc (ALEC) has received an overall TradingKey Stock Score of 5.79/10, indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued. Institutional ownership is very high, and analysts have recently rated the stock as "Hold" with a target price …

Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - WGS

Levi & Korsinsky, LLP has issued a reminder to investors in GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit. The lawsuit alleges that GeneDx management misled investors about deteriorating reimbursement rates and margin compression between April 16, 2025, and May …

Earnings Preview: Revvity to Report Financial Results Pre-market on August 04

This article announces that Revvity (NYSE: RVTY) is scheduled to release its financial results before the market opens on August 04. Analysts predict the company will report earnings of $1.16 per share, with revenue expectations around $677.67 million for the current fiscal quarter. These …

IQVIA Holdings (IQV) Earnings Beat Keeps Fair Value In Focus

IQVIA Holdings (IQV) reported strong Q2 results, exceeding analyst estimates and raising full-year guidance, leading to a significant 55.07% share price return over 90 days. Despite this positive momentum and a narrative-pegged fair value of $232 suggesting the stock is 4.7% overvalued at its …

CGON|CG Oncology Inc|Price:69.180|Chg%:-3.440

This article provides a comprehensive stock analysis of CG Oncology Inc (CGON) from TradingKey. The company's fundamentals are considered healthy with high growth potential, and its valuation is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have given a "Buy" rating …

Fulgent Genetics Inc (FLGT) Financial Health: Profitability & Balance Sheet Analysis

Fulgent Genetics Inc (FLGT) currently holds a financial score of 6.89, placing it 52nd out of 75 in the Healthcare Providers & Services industry, indicating stable financial health and high operating efficiency. Despite this, its latest quarterly revenue decreased by 3.16% year-over-year to $71.14M, …

AGL|agilon health inc|Price:92.730|Chg%:-6.410

This article provides a detailed stock analysis of agilon health inc (AGL), including real-time quotes, key financial figures, insights into its fundamentals and growth potential, and analyst ratings. It highlights that agilon health inc is a healthcare company focused on empowering primary care physicians …

Charles River Laboratories International Inc (CRL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Charles River Laboratories International Inc (CRL), noting its current valuation score and ranking within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio, comparing it to recent highs and lows, but states that …

MDxHealth SA (MDXH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MDxHealth SA (MDXH), covering its stock price, support and resistance levels, and various technical indicators and moving averages. As of July 29, 2026, MDXH has a price momentum score of 4.52 and is trading between a resistance …

VCYT|Veracyte Inc|Price:55.730|Chg%:+0.080

This article provides a comprehensive analysis of Veracyte Inc (VCYT), highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It details the company's diagnostic products for various cancers, institutional ownership, and analyst ratings, indicating a positive …

Charles River Laboratories International Inc. Stock Rises 7.2%, Outperforms Peers

Shares of Charles River Laboratories International Inc. (CRL) experienced a significant rise of 7.2% on Wednesday, outperforming its competitors. This strong performance indicates a positive market reaction to the company's recent activities or broader sector trends.

Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

This article first appeared on GuruFocus. Total Revenue: $71.6 million, up 30% year-over-year. MRD Revenue: $66.2 million, up 33% year-over-year; core MRD revenue (excluding milestones) grew 49%. Clinical Revenue (MRD): Increased 53% year-over-year, driven by a 43% increase in testing volumes and a 7% …

ARVN|Arvinas Inc|Price:8.230|Chg%:+0.030

This article provides a comprehensive stock analysis of Arvinas Inc (ARVN), highlighting its healthy fundamentals, significant growth potential, and "fairly valued" status. It notes high institutional ownership and multiple "Buy" ratings from analysts, despite a medium-term expectation for the stock price to trend down …

MDxHealth SA Revenue Breakdown – NASDAQ:MDXH

MDxHealth SA (NASDAQ: MDXH) generated $107.88 million USD in revenue last year, primarily from its Tissue-based segment, which contributed $81.49 million USD. The majority of its revenue, $107.88 million USD, originated from the United States, Europe, and the Rest of the World.

Behavioral Patterns of FLGT and Institutional Flows

This article analyzes behavioral patterns and institutional flows for Fulgent Genetics Inc. (NASDAQ: FLGT), suggesting a near-term neutral sentiment that may pause mid- and long-term weakness. It highlights an exceptional 96.0:1 risk-reward setup targeting a 26.9% gain with minimal risk. The report also provides …

Medpace Holdings (MEDP) Is Up 10.8% After Boosting 2026 Outlook And Retiring 17% Of Shares - Has The Bull Case Changed?

Medpace Holdings (MEDP) saw a 10.8% stock increase after reporting strong Q2 2026 results, boosting its 2026 outlook, and completing a significant share repurchase program that retired 17.25% of its shares. The company now projects 2026 revenue between US$2.81 billion and US$2.89 billion, with …

PGNY|Progyny Inc|Price:31.360|Chg%:+0.600

This article from TradingKey provides a comprehensive stock analysis of Progyny Inc (PGNY), highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts. It notes that the company is fairly valued with high institutional ownership, although its technical performance doesn't fully support …

Labcorp Holdings Inc stock hits 52-week high at 315.82 USD

Labcorp Holdings Inc (LH) stock has reached a new 52-week high of $315.82, following a 20.83% increase over the past year and 23% year-to-date returns. The company recently reported strong Q2 results, with adjusted earnings of $4.99 per share and revenue of $3.73 billion, …

ICON PLC earnings beat by $0.01, revenue topped estimates

ICON PLC reported second-quarter earnings per share (EPS) of $2.56, surpassing analyst estimates by $0.01. The company's revenue for the quarter reached $2.06 billion, exceeding the consensus estimate of $2 billion. ICON PLC's stock price has increased by 57.50% in the last three months, …

QIAGEN Number of Employees 2026 | Employee Count & Headcount Data

QIAGEN NV (QGEN) has approximately 5,617 employees worldwide as of March 2026, marking a 6.6% decline from 2023. The company is actively hiring, with 272 job postings in 2026, though new postings per month have decreased. The workforce is primarily concentrated in the United …

ICON Reports Second Quarter 2026 Results

ICON plc reported its financial results for the second quarter ended June 30, 2026, with revenue reaching $2,063.5 million and adjusted diluted earnings per share of $2.56. The company reaffirmed its full-year 2026 financial guidance, anticipating revenue between $7,850 and $8,150 million, and adjusted …

IQVIA Holdings Inc. (IQV) Stock Price | Live Quotes & Charts | NYSE

This page provides live quotes and charts for IQVIA Holdings Inc. (IQV) stock on the NYSE. It shows a current stock price of $247.56, up $4.62 (1.90%), but notes that prices are delayed. The article also mentions the absence of analyst ratings and earnings …

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $248.86, Implies 6% Upside

The average 12-month price target for Quest Diagnostics Incorporated (DGX) stock has been raised by analysts from $246.6 to $248.86, indicating an approximate 6% potential upside from its July 29th closing price. The consensus rating from 20 analysts remains a "Buy," with 9 Buys, …

OPKO Health Number of Employees 2026 | Employee Count & Headcount Data

OPKO Health (NASDAQ: OPK) had approximately 2,275 employees worldwide as of March 2026, representing a 13.9% decline from 2023. Despite this decline, the company is actively hiring, with 129 active job postings in 2026, a 71.6% increase from the previous year. The workforce is …

ALXO|ALX Oncology Holdings Inc|Price:1.950|Chg%:-0.040

This article provides a comprehensive stock analysis of ALX Oncology Holdings Inc (ALXO), highlighting its relatively weak fundamentals but high growth potential and fair valuation within the Biotechnology & Medical Research industry. The company's lead product candidate, evorpacept, is a CD47 blocking therapeutic, and …

PAR|PAR Technology Corp|Price:16.560|Chg%:-0.800

This article provides a comprehensive stock analysis of PAR Technology Corp (PAR), highlighting its strong fundamentals, high growth potential, and "fairly valued" status. Despite recent weak market performance, the company shows solid growth in revenue and net income. Analysts currently rate PAR as a …

Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Adaptive Biotechnologies Corp (AD

VSTM|Verastem Inc|Price:6.013|Chg%:-0.217

This article provides a comprehensive stock analysis of Verastem Inc (VSTM) by TradingKey, highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The company's stock is rated "Buy" by multiple analysts with a target price …

RCUS|Arcus Biosciences Inc|Price:26.470|Chg%:-0.580

This article provides a comprehensive stock analysis of Arcus Biosciences Inc (RCUS) by TradingKey, highlighting its stable fundamentals, significant growth potential, and a "fairly valued" rating within the Biotechnology & Medical Research industry. The company, a clinical-stage biopharmaceutical firm focused on cancer therapies, shows …

Tempus AI buys Personalis to strengthen AI-driven cancer monitoring platform

Tempus AI is acquiring Personalis in a $1.5 billion deal to expand its AI-driven cancer monitoring platform. The acquisition will integrate Personalis' NeXT Personal tumor-informed liquid biopsy platform with Tempus' clinical data ecosystem to enhance cancer detection and personalized treatment. This move targets the …

Insider at Natera, Inc. (NTRA) sells shares to cover RSU tax obligations

Natera, Inc.'s Secretary and Chief Legal Officer, Daniel Rabinowitz, sold a total of 1,887 shares of common stock on July 27-28, 2026. These sales, valued at approximately $485,000, were executed to cover tax withholding obligations stemming from the vesting of Restricted Stock Units (RSUs). …